2008-07-02 15:19:18 - www.companiesandmarkets.com adds new report - Premium Company Profile - Elan Corporation plc

www.companiesandmarkets.com/Summary-Company-Profile/Premium-Comp ..
Introduction

Elan is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing therapies in neurodegenerative diseases, autoimmune diseases, and severe pain. The company currently markets anti-infectives Maxipime and Azactam, as well as Tysabri, its landmark product co-developed with Biogen Idec.



During fiscal 2006, Elan generated approximately 51% of total revenues from EDT division

and 49% from biopharmaceuticals division. The company earns revenues from product sales, royalties and licenses. Elan now has a balanced contribution from product sales and royalties, licenses, collaboration and other.



Tysabri is expected to be the main growth driver of revenues for Elan to 2010, generating sales growth of +$1,832 million during the period 2006-2010. Currently, Tysabri is indicated for the treatment for relapsing forms of multiple sclerosis (MS). The drug is currently in Phase III clinical trial for Crohn’s Disease.



Scope

Access all the important information and analysis on a company in a single report
Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company’s adjusted five year financial data along with key ratios and market capitalization


Highlights



Reasons to Purchase